Skip to content

Author

Michael J. Eck

We have 1 of 8 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Towards better outcomes for epidermal growth factor receptor L858R+ lung cancer patients: mutant-selective allosteric inhibitors and the potential for double-drugging.

Next-generation EGFR inhibitors with a particular focus on allosteric inhibitors developed for L858R-mutant NSCLC are surveyed, offering the possibility of double-drugging the mutant receptor to achieve deeper and more durable responses for EGFR L858R+ patients.

Michael J. Eck, David A. Scott · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.